References
- Stein GE, Craig WA. Tigecycline: a critical analysis. Clin In-fect Dis 2006; 43: 518–24.
- Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 (Suppl 5): S303–14.
- Saner FH, Heder M, Rath P, Gensicke J, Radtke A, Drühe N, et al. Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia. Liver Transp. 2006; 12: 1689–92.
- Mutioz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J Infect Dis 2006; 38: 1081–4.
- PMaclayton DO, Hall RG Pharmacological treatment op-tions for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007; 41 (2): 235-44. Epub 2007 Mar 7. Review. PMID: 17346938 [PubMed - in-dexed for MEDLINE].
- Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacother 2007; 27 (7): 1052–7.
- Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27 (8): 1198–1201.
- Curdo D, Fernandez F, Duret F. Initial use of tigecycline in Argentina (article in Spanish). Rev Chilena Infectol 2007; 24 (6): 497–499.
- Maroko R, Cooper A, Dukart G, Dartois N Gandjini H. Re-sults of Phase 3 study comparing a tigecycline (TGC) regimen with an imipenem/cilastatin (IMI) regimen in treatment of pa-tients (Pts) with hospital-acquired pneumonia (HAP). L-730 Wyeth Pharmaceuticals.
- Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and noso- comial pneumonia. Diagn Microbiol Infect Dis 2005; 52: 187-93.
- Mundalidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents and Chemother 2005; 49: 220–9.
- Mensa J, Soriano A, Martinez JA. Initial empiric antimi-crobial therapy for suspected severe infections caused by multi-drug resistant pathogens. Enferm Infecc Microbiol Clin, Monogr 2006; 5: 44–52.
- Betriu C, Rodriguez-Avial I, Sanchez BA, Gómez M, Pi-cazo JJ. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas mal-tophilia. J Antimicrob Chemother 2002; 50: 758-9.